[A17-64] Abiraterone acetate (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 07.06.2018
Project no.:
A17-64
Commission:
Commission awarded on 15.12.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)
Proof of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-26 | Abiraterone acetate (prostate cancer) - Addendum to Commission A17-64 | Commission completed |
| A13-06 | Abiraterone acetate (New therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A11-20 | Abiraterone acetate - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2018-06-07 A G-BA decision was published.